Related Experiment Video
Updated: Oct 3, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking
Yining Wang1, Pengfei Li1, Marla Lavrijsen1
1Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, room Na-1005, Wytemaweg 80, NL-3015, Rotterdam, CN, The Netherlands.
Abstract:
Given the structural similarities of the viral enzymes of different coronaviruses (CoVs), we investigated the potency of the anti-SARS-CoV-2 agents boceprevir and GC376 for counteracting seasonal coronavirus infections. In contrast to previous findings that both boceprevir and GC376 are potent inhibitors of the main protease (Mpro) of SARS-CoV-2, we found that GC376 is much more effective than boceprevir in inhibiting SARS-CoV-2 and three seasonal CoVs (NL63, 229E, and OC43) in cell culture models. However, these results are discordant with a molecular docking analysis that suggested comparable affinity of boceprevir and GC376 for the different Mpro enzymes of the four CoVs. Collectively, our results support future development of GC376 but not boceprevir (although it is an FDA-approved antiviral medication) as a pan-coronavirus antiviral agent. Furthermore, we caution against overinterpretation of in silico data when developing antiviral therapies.
Related Concept Videos
Subviral Agents
Drug Product Performance: In Vitro–In Vivo Correlation
Antimicrobial Effectiveness
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Bioequivalence of Drugs: Drugs with Multiple Indications
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

